Notice ID: d8a029c520de72edd3e76b3c0fcfe7aePresolicitation
Human Cortical Glutamatergic Neurons
Archived on March 8, 2018. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 12:00 PM UTC−05:00
- Posted
- February 16, 2018
- Notice type
- Presolicitation
- NAICS
- 325414: Biological Product (except Diagnostic) Manufacturing
Notice details
- PSC
- Q: MEDICAL SERVICES
- Last updated
- Sep 25, 2026
Identifiers
- Solicitation number
- NIHDA201800049
- Notice ID
- d8a029c520de72edd3e76b3c0fcfe7ae
Description
INTRODUCTION PURSUANT TO FAR Subpart 5.2-Synopses of Proposed Contract Actions, THIS IS A PRE-SOLICITATION NOTICE OF A PROPOSED CONTRACT TO ACTION. THIS IS A PRE-SOLICITATION NON-COMPETITIVE NOTICE OF INTENT TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) intends to award a purchase order to BrainXell, Inc. for services to grow human cortical glutamatergic neurons. BrainXell utilizes a unique, proprietary mixture of growth factors that accelerate the rate of maturation of the neurons into fully mature neurons in less than five (5) days after thawing. NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 325414 - Biological Product (except Diagnostic) Manufacturing and the small business size standard 1,250. REGULATORY AUTHORITY The resultant contract will include all applicable provisions and clauses of the Federal acquisition Requlation (FAR) in effect through the Federal Acquisition Circular (FAC) 2005-97, dated January 24, 2018. STATUTORY AUTHORITY This acquisition is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106-1 (b) (1), Soliciting from a single source. DESCRIPTION OF REQUIREMENT Project Description Title: Human Cortical Glutamatergic Neurons Background: The National Center for Advancing Translational Sciences (NCATS) focuses on getting more treatments to more patients more quickly. Several thousand genetic diseases affect humans of which only about 500 have any treatment. NCATS is directly addressing this problem by discovering new technologies and other approaches that could greatly accelerate the process of developing and deploying solutions that can be used by all translational researchers. The Therapeutics for Rare and Neglected Diseases (TRND) biology program's mission is to encourage and speed the development of new treatments for diseases with high-unmet medical needs. The group has previously developed multiple assays for quantitative high throughput screening to find novel compounds, which may be used to treat lysosomal storage diseases such as Niemann-Pick disease types A, C1 and C2. The hypothesis for this project is that neurons exhibiting Niemann-Pick disease phenotypes will have increased lysosomal accumulation and substrate accumulation in lysosomes. The contractor will grow stem cells into actual neurons that have the Niemann-Pick phenotype. The contractor will send the neurons to TRND for further testing. The contractor shall be responsible for validating the patient-derived induced pluripotent stem cells (iPSCs), producing the neurons, and assessing the quality of the neurons. Project requirements: The contractor will receive frozen iPSCs, provided by TRND, that were derived from patients with a lysosomal storage disease. The iPSCs TRND is sending out will have the disease phenotype. The contractor will thaw and culture the iPSC line to validate its quality. If necessary, the contractor will select and expand high-quality sub-colonies within the culture before neural differentiation. The contractor will produce 20 vials of human cortical glutamatergic neurons from the iPSCs lines. The cortical glutamatergic neurons will be frozen at 5 million neurons/vial in 100 ?L of freezing medium with a total batch size of 20 vials. The contractor will freeze all cells and ship them along with seeding supplements which will make it possible for the neurons to grow and survive in a 1536-well plate environment. Shipment will be overnight using a liquid nitrogen vapor shipper to TRND. Other important considerations: • Experience in large quantity production of human cortical glutamatergic neurons from iPSCs lines and capability of high repeatability of these iPSC derived neurons. • Capability to accelerate the rate of maturation of the neurons into fully mature neurons in less than five (5) days after thawing. • Understanding of the project and technical approach. Purpose and Objectives To procure human cortical glutamatergic neurons differentiated from patient-derived iPSCs for the TRND laboratory. Period of Performance Within three (3) months from time of award. CLOSING STATEMENT This synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice must include sufficient information to establish the interested parties' bona fide capabilities of providing the product or service. The price quote shall include: total price, delivery date after date, and any other information or factors that may be considered in the award decision. Such factors may include: technical approach, ability to meet or exceed the delivery date/period of performance, and cost/price. In addition the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size must be included in the response. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. The information received will normally be considered solely for the purposes of determining whether to proceed on a non-competitive basis or to conduct a competitive procurement. All responses must be received by 12:00 p.m. Eastern Standard Time, Wednesday, February 21, 2018, and reference number NIHDA201800049. Responses may be submitted electronically to Contract Specialist Mark McNally at mcnallyme@mail.nih.gov. Fax responses will not be accepted. Contracting Office Address: 6001 Executive Blvd Room 3150, MSC 9559 Bethesda, MD 20892-9559 "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency."
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
No documents available.
Lifecycle
Solicitation:
NIHDA201800049- Market Research
- Pre-Solicitation
Formal solicitation typically follows within 30–60 days. (estimate)
- Market ResearchFeb 1, 2018
Human Cortical Glutamatergic Neurons
- Pre-SolicitationCurrentFeb 16, 2018
Human Cortical Glutamatergic Neurons
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Egg-Free Influenza Vaccine Solicitation: SPE2DP26R0004 | - | Solicitation | 12/03/2026 |
Influenza Vaccine Solicitation: SPE2DP26R0003 | - | Solicitation | 12/03/2026 |
NOTICE OF INTENT – SOLE-SOURCE ACQUISITION Notice No.: The National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS), intends to award a Firm-Fixed-Price Purchase Order to Creative Biolab Inc. for culture all cells and differentiate them, expand their cell populations to more than 20 million, collect them, verify cell count, and send them back to us. Description of the Requirement The primary objective of this study is to sequence and analyze the 4q35 locus on Chromosome 4 for several years. This locus is a gene-poor and extremely long (>100K) region of DNA that consists of many repetitive sequences which makes sequencing and analysis extremely difficult. To sequence this locus using Nanopore Sequencing technology. To expand the number of samples for our experiment, we looked for a company that can handle numerous cell lines and follow the protocol that we provide. Creative Biolabs is the only company/research institute that has been able to perform differentiation within 3 months and has the ability to follow our protocol with numerous cell lines. Justification for the Proposed Sole-Source Acquisition The Government intends to solicit from a single source pursuant to FAR 6.302-1, Only One Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Only Creative Biolabs was willing to follow our exact protocol and had the logistical capacity to handle the large number of cell lines that we need to analyze, which is vital to research at the National Institute of Environmental Health Sciences. Response Information This notice is not a request for competitive quotations or proposals. However, interested parties that believe they can meet the Government's requirements may submit a capability statement demonstrating their ability to provide the required preventive maintenance and remedial repair services for the specified instrument and meet all applicable technical and operational requirements. The Government will review timely submissions to determine whether another responsible source is capable of satisfying the requirement and whether a competitive acquisition is appropriate. The Government anticipates making an award approximately five (5) calendar days after the closing date of this notice, unless the Government determines that another responsible source can satisfy the requirement. Capability statements must be submitted electronically to verne.griffin@nih.gov no later than 9:00 a.m. EDT on November 13, 2026. Please reference Notice No. 75N98027Q00053 in the subject line of the submission. | - | Pre-Solicitation | 11/12/2026 |
This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR Part 12. This announcement constitutes the only solicitation. Proposals are being requested and a separate written solicitation will not be issued. Solicitation number 12639527R0001 is issued as a Request for Proposal (RFP) for the purchase and storage of Foot and Mouth Disease (FMD) Vaccine Antigen Concentrate (VAC), conversion of Government owed VAC into usable vaccine, and the direct purchase of finished vaccine. This acquisition is not set-aside for small business concerns. The applicable North American Industry Classification Standard Code is 325414. The small business size standard is 1,250. This acquisition is an unrestricted requirement. All responsible sources may submit a proposal which will be considered by the agency. | - | Combined Synopsis | 11/10/2026 |
The following VISN 12 Locations have a need for delivery of Blood and Blood Products. Jesse Brown VAMC, 820 South Damen Ave, Chicago, IL 60612 Lovell Federal Health Care Center, 3001 Green Bay Road, North Chicago, IL 60064 Hines VAMC, 5000 South 5th Ave, Hines, IL 60141 William S Middleton VAMC, 2500 Overlook Terrace, Madison, WI 53705. Tomah VAMC, 500 E. Veterans Street, Tomah, WI 54660 Zablocki VAMC, 5000 W. National Ave, Milwaukee WI 53295. The Blood and Blood Products will be defined in RFQ# 36C25226Q0606. | - | Awarded | Open |
Additional Details
Solicitation Number
NIHDA201800049
Archive Date
Mar 8, 2018